Last week, readers were most interested in a story about QuidelOrtho's ongoing restructuring to support profitability.

The UK-based firm is developing its initial panel tests for Gram-negative bacteria with tests for Gram-positive bacteria and ...

The test will measure levels of the 14-3-3eta protein, which is used in the diagnosis and management of inflammatory diseases including rheumatoid arthritis.

The flow cytometry-based assay measures the expression of the protein FcyR11a as a biomarker for cardiovascular risk.

The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

NEW YORK – Autoimmune testing firm Exagen on Tuesday announced its Q3 revenues declined 7 percent year over year. For the three months ended Sept. 30, the firm posted revenues of $12.5 million, down ...

Due to an error by the company the article incorrectly previously stated the firm received Class C certification. It has been corrected to state that it received ...

NEW YORK – Israel Institute of Technology spinout MetaSight Diagnostics announced on Wednesday that it has closed an $8 million oversubscribed Series A financing round. The round was led by new ...

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

NEW YORK – AI diagnostics firm Tempus said on Tuesday that it has inked a deal with Roche's Flatiron Health that will allow healthcare providers to order Tempus' genomic cancer tests through ...